Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma.
Gutzmer R, Leiter U, Mohr P, Kähler KC, Ascierto PA, Scalvenzi M, Peris K, Pérez-Pastor GM, Fernández-de-Misa R, Botella-Estrada R, Hunger RE, Martelli S, Güneli N, Arntz R, Hauschild A. Gutzmer R, et al. Among authors: mohr p. BMC Cancer. 2024 Nov 14;24(1):1401. doi: 10.1186/s12885-024-13101-z. BMC Cancer. 2024. PMID: 39538176 Free PMC article.
Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.
Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, Terheyden P, Krause-Bergmann A, Schulze HJ, Hassel J, Lahner N, Wollina U, Ziller F, Utikal J, Hafner C, Ulrich J, Machens HG, Weishaupt C, Hauschild A, Mohr P, Pföhler C, Maurer J, Wolff P, Windemuth-Kieselbach C, Schadendorf D, Livingstone E; Dermatologic Cooperative Oncology Group (DeCOG). Hillen U, et al. Among authors: mohr p. Eur J Cancer. 2018 Jun;96:34-43. doi: 10.1016/j.ejca.2018.01.075. Epub 2018 Apr 14. Eur J Cancer. 2018. PMID: 29665511
Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS.
Kaatz M, Mohr P, Livingstone E, Weichenthal M, Kreuter A, Pföhler C, Leiter U, Ulrich J, Utikal JS, Gutzmer R, Herbst R, Schadendorf D. Kaatz M, et al. Among authors: mohr p. Acta Derm Venereol. 2022 Apr 13;102:adv00695. doi: 10.2340/actadv.v102.293. Acta Derm Venereol. 2022. PMID: 35199180 Free PMC article.
Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors.
Bossi P, Ascierto PA, Basset-Seguin N, Dreno B, Dummer R, Hauschild A, Mohr P, Kaufmann R, Pellacani G, Puig S, Moreno-Ramírez D, Robert C, Stratigos A, Gutzmer R, Queirolo P, Quaglino P, Peris K. Bossi P, et al. Among authors: mohr p. Crit Rev Oncol Hematol. 2023 Sep;189:104066. doi: 10.1016/j.critrevonc.2023.104066. Epub 2023 Jul 11. Crit Rev Oncol Hematol. 2023. PMID: 37442495 Free article. Review.
[Adjuvant systemic treatment of melanoma].
Kähler KC, Egberts F, Hauschild A, Mohr P. Kähler KC, et al. Among authors: mohr p. Hautarzt. 2011 Jun;62(6):414, 416-22. doi: 10.1007/s00105-010-2040-6. Hautarzt. 2011. PMID: 21656113 Review. German.
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Spillner AN, Eckhardt S, Schadendorf D; DeCOG. Becker JC, et al. Among authors: mohr p. Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11. Lancet. 2023. PMID: 37451295 Clinical Trial.
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.
Wohlfeil SA, Kranzmann L, Weiß C, von Wasielewski I, Klespe KC, Kähler KC, Weichenthal M, Schadendorf D, Zimmer L, Mohr P, Meier F, Pfoehler C, Berking C, Heppt MV, Herbst R, Kreuter A, Gutzmer R, Ulrich J, Meiss F, Gebhardt C, Dippel E, Leiter U, Schilling B, Ugurel S, Utikal J. Wohlfeil SA, et al. Among authors: mohr p. Int J Cancer. 2024 Nov 15;155(10):1808-1823. doi: 10.1002/ijc.35078. Epub 2024 Jul 8. Int J Cancer. 2024. PMID: 38975881
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.
Eigentler TK, Schlaak M, Hassel JC, Loquai C, Stoffels I, Gutzmer R, Pätzold S, Mohr P, Keller U, Starz H, Ulrich J, Tsianakas A, Kähler K, Hauschild A, Janssen E, Schuler-Thurner B, Weide B, Garbe C. Eigentler TK, et al. Among authors: mohr p. J Immunother. 2014 Sep;37(7):374-81. doi: 10.1097/CJI.0000000000000046. J Immunother. 2014. PMID: 25075567
594 results